multiple dose studies [Design Issues]

posted by dshah  – India, 2024-03-12 18:37 (825 d 01:08 ago) – Posting: # 23905
Views: 5,025

Hello Loky do!

❝ I'm a little confused :confused: why to analyze solifenacin as it is immediate release and the concern towards tamsulosin as it is the delayed release one, even if I took into consideration the washout of both, are the results of solifenacin, in this case, affect those of tamsulosin?

❝

Kindly refer section 3 of EMA guideline on FDC.
[image]

Considering as a sponsor, the analysis of solifenacin adds a cost. But as a regulator- if you are taking the sample- why it is not analyzed? Any SE relation with PK would not be feasible, then.

Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
100 visitors (0 registered, 100 guests [including 9 identified bots]).
Forum time: 20:45 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5